Source comparison
Oral vs Injectable KPV Dosing
Oral and subcutaneous KPV use the same daily milligram range. The difference is destination, not dose size. Best target Gut, IBD, colitis Systemic, joints, widespread skin Absorption PepT1 transporter in gut lining Direct into circulation Self-targeting Yes, P
This comparison does not assign a generated winner or score.
- Oral and subcutaneous KPV use the same daily milligram range. The difference is destination, not dose size.
- Best target
- Gut, IBD, colitis
- Systemic, joints, widespread skin
- Absorption
- PepT1 transporter in gut lining
- Direct into circulation
- Self-targeting
- Yes, PepT1 rises with inflammation
- No
- Typical onset
- 2-4 weeks
- 1-2 weeks
- Timing
- Empty stomach, 30 min before food
- Anytime, rotate sites
- Daily dose
- 200-500 mcg
- The common error is assuming injection is always stronger. For gut conditions it is not. Oral KPV places the peptide exactly where colitis occurs, and the PepT1 upregulation during inflammation creates a delivery advantage injection cannot copy (Dalmasso et al., 2008). For systemic targets the logic flips, and subcutaneous wins. Many users separate these by time of day as well, depending on goal.